Lupin shares rise nearly 3% on launch of Rivaroxaban Tablets USP, in the US
Lupin's shares increased by 21.51% over the past year. However, year-to-date (YTD), the stock has decreased by 14.21%. Over the last six months, the price fell by 10.12%, while in the past three months, it dropped by 4.86%. In the last month, the ...
By Nishtha Awasthi, ETMarkets.com | Updated:
ETMarkets.com
The shares of Indian pharmaceutical company Lupin rose 2.6% to their day’s high of Rs 2,081.95 on the BSE on Monday, March 10, after the company launched its Rivaroxaban Tablets USP, 2.5mg in the United States.
“Global pharma major Lupin Limited (Lupin) today announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the U.S. FDA,” the company said in a regulatory filing.
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto Tablets, 2.5 mg, meaning it has the same active ingredient, absorption rate, and therapeutic effect as the Janssen Pharmaceuticals product.
It is prescribed to reduce the risk of major cardiovascular events, such as heart attacks and strokes, in patients with coronary artery disease (CAD). Additionally, it helps lower the risk of major thrombotic vascular events in individuals with peripheral artery disease (PAD), including those who have recently undergone lower extremity revascularization due to symptomatic PAD.
Rivaroxaban Tablets USP, 2.5 mg (RLD Xarelto) had estimated annual sales of USD 446 million in the U.S. (IQVIA MAT January 2025), the company informed.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
Lupin share price history
Over the last year, the shares of Lupin rose by 21.51%. However, the year-to-date (YTD) change indicates a decline of 14.21%. Over the past six months, the price fell by 10.12%, while the three-month period recorded a decrease of 4.86%. In the past month, the price dropped by 7.76%.
On Friday, the shares of Lupin closed flat at Rs 2,028.90 on the BSE.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
“Global pharma major Lupin Limited (Lupin) today announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the U.S. FDA,” the company said in a regulatory filing.
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto Tablets, 2.5 mg, meaning it has the same active ingredient, absorption rate, and therapeutic effect as the Janssen Pharmaceuticals product.
It is prescribed to reduce the risk of major cardiovascular events, such as heart attacks and strokes, in patients with coronary artery disease (CAD). Additionally, it helps lower the risk of major thrombotic vascular events in individuals with peripheral artery disease (PAD), including those who have recently undergone lower extremity revascularization due to symptomatic PAD.
Rivaroxaban Tablets USP, 2.5 mg (RLD Xarelto) had estimated annual sales of USD 446 million in the U.S. (IQVIA MAT January 2025), the company informed.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
ADVERTISEMENT
Lupin share price history
Over the last year, the shares of Lupin rose by 21.51%. However, the year-to-date (YTD) change indicates a decline of 14.21%. Over the past six months, the price fell by 10.12%, while the three-month period recorded a decrease of 4.86%. In the past month, the price dropped by 7.76%.
On Friday, the shares of Lupin closed flat at Rs 2,028.90 on the BSE.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Good home show to help Lupin limit fallout of US woesADVERTISEMENT
